Navigation Links
Regenerative Medicine and Stem Cells Market Deals Analysis in New Research Report at ReportsnReports.com
Date:2/12/2013

sp;What sublicensing and subcontracting provisions have been agreed?
  •     Which boilerplate clauses does the company insist upon?
  •     Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  •     Which jurisdiction does the company insist upon for agreement law?

    • The initial chapters of this report provide an orientation of drug deal making and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in regenerative medicine and stem cells deal making since 2009, including details of average headline, upfront, milestone and royalty terms.

    Chapter 3 provides a review of the leading regenerative medicine and stem cells deals since 2009. Deals are listed by headline value, signed by big pharma, most active big pharma, and most active of all bio pharma companies.

    Chapter 4 provides a comprehensive listing of the top 50 big pharma companies with a brief summary followed by a comprehensive listing of regenerative medicine and stem cells deals, as well as contract documents available in the public domain.

    Chapter 5 provides a comprehensive and detailed review of regenerative medicine and stem cells partnering deals signed and announced since 2009, where a contract document is available in the public domain.

    In addition, a comprehensive appendix is provided organized by regenerative medicine and stem cells partnering company A-Z, deal type definitions and regenerative medicine and stem cells partnering agreements example. Each deal title links via Web link to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

    In conclusion, thi
    '/>"/>

    Source: PRWeb
    Copyright©2012 Vocus, Inc.
    All rights reserved

    0

    GOOD

    Page: 1 2 3 4

    Related biology technology :

    1. Shire Regenerative Medicine Initiates Phase 3 Study of ABH001 for Patients with Epidermolysis Bullosa
    2. The Alliance for Regenerative Medicine forms Tissue Engineering and Biomaterials Committee
    3. Dr. Jeff Jonas Appointed President of Shire Regenerative Medicine Business and Joins Shire Leadership Team
    4. IntelliCell BioSciences Announces It Will Present and Run Workshop at the 10th Annual Commercialization of Regenerative Medicine in London
    5. Neuralstem CEO to Present at the World Stem Cells and Regenerative Medicine Congress in London
    6. Regenerative Sciences Receives $2M Investment for Orthopedic Stem Cell Initiatives
    7. ODT Forum Presents Regenerative Technologies
    8. Palm Beach Residents to Learn How the Future of Regenerative Medicine Will Combat Aging
    9. EastBridge Investment Group Announces Completion of its Merger with Cellular Biomedicine Group - Shareholder Conference Call to be held February 8th
    10. ALCAT Pioneer, Roger Deutsch, to Address "Food Allergies and Intolerances" at the Institute of Functional Medicine Conference in Tampa, February 8-10
    11. Southwest Integrative Medicine Offers Free eBook "Do Your Hormones Need Balancing?"
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/17/2013)... German . ... eye, you can see which branch a bird is sitting ... through the telephoto lens for high-magnification images requires considerable skill. ... to study proteins, the active biomolecules of cells. , Olga ... Systems Biology, and her colleagues have now come up with ...
    (Date:5/17/2013)... 2013 The new Public-Private Partnership (PPP) ... the association’s recent annual meeting drew praise from community ... Kroes, who called the action “a huge step forward ... to European innovation.” , The Board of Stakeholders voted ... Photonics PPP at its 29 April meeting in Brussels, ...
    (Date:5/17/2013)... 17, 2013 New interactive ... innovative thought leaders of the medical device industry ... conference and expo, from June 18-20 in ... http://photos.prnewswire.com/prnh/20130517/613829 ) , These ... industry professionals practical presentations and implementable solutions on ...
    (Date:5/17/2013)... May 17, 2013  Yongye International, Inc. (NASDAQ: ... developer, manufacturer, and distributor of crop nutrient products in ... today announced that, on May 16, 2013, the special ... (the "Board of Directors") was provided a letter (the ... Kong ) Limited ("Abax") to Full Alliance International ...
    Breaking Biology Technology:Proteome atlas for the tuberculosis pathogen 2Proteome atlas for the tuberculosis pathogen 3SPIE Joins in Praise for ‘Huge Step Forward’ for Innovation R&D Enabled by Photonics21 Actions 2SPIE Joins in Praise for ‘Huge Step Forward’ for Innovation R&D Enabled by Photonics21 Actions 3MedTech Innovate Seminars: New Interactive Learning Forums at 2013 MD&M East 2Yongye International Provides Update on Status of Proposed Go Private Offer 2Yongye International Provides Update on Status of Proposed Go Private Offer 3Yongye International Provides Update on Status of Proposed Go Private Offer 4
    ... LUND, Sweden, January 18 ,ThromboGenics NV (Euronext ... (Nordic Exchange: BINV) announce today that they,have ... Denmark to,initiate a Phase I clinical trial ... a monoclonal antibody that targets the angiogenic ...
    ... CLAREMONT, Calif., Jan. 17 /Xinhua-PRNewswire-FirstCall/ --,Kiwa Bio-Tech ... annual,management meetings including yearend business review, planning ... commenced in,Xiaotangshan, Beijing on January 11, 2008., ... staff from Kiwa,s corporate,headquarters in Beijing, and ...
    ... Types Broadens Project Coalition with Addition of ... Misys Healthcare, CHICAGO, Jan. 17 The HL7 ... starts 2008 on a strong,note adding four new benefactors ... Systems joined in the fall of 2007,ImageTek, Inc. in ...
    Cached Biology Technology:ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer 2ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer 3ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer 4ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer 5Kiwa Holds 2007 Annual Management Meetings and Employee Recognition Ceremonies in Beijing 2Kiwa Holds 2007 Annual Management Meetings and Employee Recognition Ceremonies in Beijing 3New Benefactors Show Support for CDA4CDT: 2New Benefactors Show Support for CDA4CDT: 3New Benefactors Show Support for CDA4CDT: 4New Benefactors Show Support for CDA4CDT: 5New Benefactors Show Support for CDA4CDT: 6New Benefactors Show Support for CDA4CDT: 7
    (Date:5/17/2013)... the white noise of the South, but the night belongs ... air hangs heavy from the humidity and the sounds of ... species of frogs, toads and salamanders, is the center of ... swamps are the auditorium for their symphonic choruses, the scientists ... or ARMI, have front-row seats. , Amphibians, which ...
    (Date:5/17/2013)... Why Tibetan antelope can live at elevations of ... research published in Nature Communications , investigators ... evidence that some genetic factors may be associated ... The data in this work will also provide ... biology of other ruminant species. , The Tibetan ...
    (Date:5/17/2013)... team of scientists using a new X-ray method recorded ... frog embryo in greater detail than ever before., This ... and the search for new treatments for genetic diseases., ... Technologie in Germany, in collaboration with the Advanced Photon ... Laboratory, released the most precise depiction ever of the ...
    Breaking Biology News(10 mins):Front-row seats to climate change 2Front-row seats to climate change 3Front-row seats to climate change 4The genome sequence of Tibetan antelope sheds new light on high-altitude adaptation 2New X-ray method shows how frog embryos could help thwart disease 2
    ... scientist, explorer and conservationist, will receive the Academy of ... He is the first Australian to receive the award ... leading thinkers and writers, Flannery has discovered more than ... has published more than 130 peer-reviewed scientific papers and ...
    ... that a certain class of RNA (known as long non-protein-coding ... infection. These findings, published today in the online journal ... at the body,s response to viral infection. "To our ... technology to clearly demonstrate that lncRNAs are involved in the ...
    ... Ohio New research links three molecules to a critical ... myeloma, a presently incurable cancer of the blood. , The ... and other blood cancers, according to researchers at The Ohio ... Richard J. Solove Research Institute (OSUCCC James) who led ...
    Cached Biology News:Scientist Tim Flannery is first Austrailian to receive Joseph Leidy Award 2A new player in the innate immunity game? 2Study identifies key molecules in multiple myeloma 2
    ... XIII in both reduced and non-reduced forms. It ... or human Factor XII. Factor XIII is a ... two subunits. Factor XIII-A is the catalytic subunit ... XIII is present in plasma as an Alpha2Beta2 ...
    Anti-CaM kinase II recognizes the enzymes a subunit (6) and reacts with tissue from all mammalian species tested, as well as with chicken and frog tissues....
    Ca2+ Channel Ca gamma 2 Purified Anti-Mouse, Anti-Rat, Anti-Human clone Polyclonal, Isotype Rabbit Ig, 50 µl Consult technical datasheet for details....
    Goat polyclonal to Centaurin alpha 2**...
    Biology Products: